Evidence map›Paper›PMID 40211663›Full record

ReviewMedicinal research reviews2025

Molecular Tools to Study and Control Dopaminergic Neurotransmission With Light.

Galyna Maleeva, Carlo Matera, Silvia Roda, Alessio Colleoni, Marco De Amici, Pau Gorostiza

Abstract readReview
In one paragraph

Review in Medicinal research reviews, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. OptoHMolecular brain · 2026
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Galyna MaleevaInstitute for Bioengineering of Catalonia (IBEC), The Barcelona Institute for Science and Technology, Barcelona, Spain.ORCID 0000-0002-1379-1521
Carlo MateraDepartment of Pharmaceutical Sciences, University of Milan, Milan, Italy.ORCID 0000-0001-6939-3859
Silvia RodaDepartment of Pharmaceutical Sciences, University of Milan, Milan, Italy.
Alessio ColleoniDepartment of Pharmaceutical Sciences, University of Milan, Milan, Italy.
Marco De AmiciDepartment of Pharmaceutical Sciences, University of Milan, Milan, Italy.
Pau GorostizaInstitute for Bioengineering of Catalonia (IBEC), The Barcelona Institute for Science and Technology, Barcelona, Spain.ORCID 0000-0002-7268-5577

Funding

This research was funded by the EU Horizon 2020 Framework Programme for Research and Innovation, including the European Innovation Council Pathfinder (Phototheraport, 101130883), Human Brain Project (WaveScalES, SGA3, 945539), and Information and Communication Technologies (Deeper, ICT-36-2020-101016787). It was also supported by the Government of Catalonia (CERCA Programme; AGAUR 2021-SGR-01410; AGAUR INNOVADORS 2022 INNOV 00045; AGAUR PERISSLT033/23/000067; AGAUR PRODUCTE 2023 PROD 00073); by the Spanish Ministry of Science and Innovation (DEEP RED, grant PID2019-111493RB-I00; EPILLUM, grants AEI/10.13039/501100011033, PID2022-142609OB-I00; and Research Network in Biomedicine eBrains-Spain, RED2022-134823-E). G.M. was supported by a Ramón y Cajal Investigator grant (RYC2021-033056-I financed by MCIN/AEI/10.13039/501100011033 and by the European Union NextGeneration EU/PRTR) and was financed by DOPAMAP Project PID2023-151770OA-I00 (financed by MCIU/AEI/10.13039/501100011033 and by FEDER, EU). A.C. was supported by the European Union-Next Generation EU, Mission 4, Component 1, CUP J53C24002040004 (PhD fellowship DM 630/2024).
6 · The paper itself

Abstract

Dopaminergic neurotransmission is involved in several important brain functions, such as motor control, learning, reward-motivated behavior, and emotions. Dysfunctions of dopaminergic system may lead to the development of various neurological and psychiatric disorders, like Parkinson's disease, schizophrenia, depression, and addictions. Despite years of sustained research, it is not fully established how dopaminergic neurotransmission governs these important functions through a relatively small number of neurons that release dopamine. Light-driven neurotechnologies, based on the use of small light-regulated molecules or overexpression of light-regulated proteins in neurons, have greatly contributed to the advancement of our understanding of dopaminergic circuits and our ability to control them selectively. Here, we overview the current state-of-the-art of light-driven control of dopaminergic neurotransmission. While we provide a concise guideline for the readers interested in pharmacological, pharmacogenetic, and optogenetic approaches to modulate dopaminergic neurotransmission, our primary focus is on the usage of photocaged and photo-switchable small dopaminergic molecules. We argue that photopharmacology, photoswitchable molecules of varied modalities, can be employed in a wide range of experimental paradigms, providing unprecedent insights into the principles of dopaminergic control, and represent the most promising light-based therapeutic approach for spatiotemporally precise correction of dopamine-related neural functions and pathologies.

Indexed as

DopamineDopaminergic NeuronsLightSynaptic TransmissionAnimalsHumansOptogeneticsDopamineazobenzenecaged ligandscatecholaminedopamineneuromodulationneuronal circuitsoptogeneticsoptopharmacologyphotoisomerizationphotopharmacologyphotoswitch

Identifiers

PMID40211663
PMCPMC12322515

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.